News | September 18, 2025
Novo Nordisk’s Wegovy delivered 16.6% weight loss
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
Bayer Co.Lab AdVenture platform will accelerate biotech innovation through global investment networks
Includes new $1.2 billion investment in manufacturing facilities, AI and advanced digital technologies, creating hundreds of highly skilled U.S. jobs
This strategic collaboration represents the third clinical trial under Senhwa’s five-year NCI-sponsored cancer research program
EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
Raludotatug deruxtecan is a specifically engineered, potential first-in-class CDH6-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo
The survey revealed that the proportion of individuals experiencing constant thoughts about food throughout the day declined by 46 percent after starting Wegovy
Late-breaking data presented at WCLC highlight significant and sustained improvements in overall survival, including more than doubling five-year survival rates compared to chemotherapy alone
The study further confirmed that GAL-101 effectively crosses the blood-brain barrier
First fully automated, cartridge-based companion diagnostic test for colorectal cancer patients approved in the United States
Subscribe To Our Newsletter & Stay Updated
